Zura Bio (NASDAQ:ZURA) Research Coverage Started at Piper Sandler

Analysts at Piper Sandler initiated coverage on shares of Zura Bio (NASDAQ:ZURA) in a note issued to investors on Friday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $26.00 price target on the stock. Piper Sandler’s price target suggests a potential upside of 496.33% from the stock’s previous close.

Separately, Oppenheimer reiterated an “outperform” rating and set a $16.00 target price (down previously from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $18.00.

Zura Bio Trading Up 5.1 %

Shares of ZURA stock opened at $4.36 on Friday. The firm has a fifty day moving average price of $3.24 and a 200 day moving average price of $3.95. Zura Bio has a 12 month low of $2.00 and a 12 month high of $14.00.

Insiders Place Their Bets

In other news, Director Amit Munshi acquired 159,744 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were bought at an average price of $3.13 per share, with a total value of $499,998.72. Following the completion of the acquisition, the director now owns 777,384 shares in the company, valued at approximately $2,433,211.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have bought 170,926 shares of company stock valued at $534,998. 15.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC grew its holdings in shares of Zura Bio by 15.4% during the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after buying an additional 244,000 shares during the last quarter. Silverarc Capital Management LLC lifted its position in Zura Bio by 152.5% in the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after purchasing an additional 244,040 shares during the period. Eisler Capital US LLC acquired a new stake in Zura Bio in the third quarter valued at about $660,000. Raymond James & Associates lifted its position in Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock valued at $511,000 after purchasing an additional 9,481 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Zura Bio in the third quarter valued at about $224,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.